Amylyx Pharmaceuticals, Inc. (AMLX) Revenue History
Annual and quarterly revenue from 2019 to present
AMLX Revenue Over Time (2019–2025)
AMLX Revenue Growth History
1 of 5 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- -54.4%
- FY2021 revenue growth
- -100.0%
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- +1612.9%
- FY2024 revenue growth
- -77.1%
- FY2025 revenue growth
- -100.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | +100.0% |
| Q3 2025 | $0 | -100.0% |
| Q2 2025 | $0 | +100.0% |
| Q1 2025 | $0 | -100.0% |
| Q4 2024 | $-665,000 | -100.6% |
| Q3 2024 | $416K | -99.6% |
| Q2 2024 | $-1,023,000 | -101.0% |
Multi-year avg. share of annual revenue by fiscal quarter
AMLX Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 12, 2026, Amylyx Pharmaceuticals, Inc. (AMLX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
AMLX's historical revenue data shows various trends over time. Amylyx Pharmaceuticals, Inc.'s highest annual revenue of $380.8 million was recorded in 2023.
Peer Comparison
Compared to Healthcare sector peers — including IONS (+47.5% YoY), BIIB (+0.4% YoY), and MDGL (+256.8% YoY). Compare AMLX vs IONS →
AMLX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 AMLXCurrent | $0 | - | - | - | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 BIIB | $9.8B | +0.4% | -6.1% | 19.1% | |
 MDGL | $958M | +256.8% | - | -31.3% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% |
AMLX Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $-525,000 | - | $-153,291,000 | - |
| 2024 | $87.4M | -77.1% | $45.2M | 51.8% | $-314,731,000 | -360.2% |
| 2023 | $380.8M | +1612.9% | $355.3M | 93.3% | $38.8M | 10.2% |
| 2022 | $22.2M | - | $19.2M | 86.5% | $-201,341,000 | -905.7% |
| 2021 | $0 | -100.0% | $0 | - | $-82,688,000 | - |
| 2020 | $650K | -54.4% | $-23,944,000 | -3683.7% | $-39,005,000 | -6000.8% |
| 2019 | $1.4M | - | $-10,473,000 | -734.4% | $-13,554,000 | -950.5% |
What if you invested $1,000 in AMLX back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in AMLX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs AMLX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationAMLX vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowAMLX — Frequently Asked Questions
Quick answers to the most common questions about buying AMLX stock.
Is AMLX's revenue growth accelerating or slowing?
AMLX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is AMLX's revenue history from 2019 to 2026?
Amylyx Pharmaceuticals, Inc. (AMLX) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is AMLX's long-term revenue growth rate (CAGR)?
Amylyx Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for AMLX.
Why does AMLX's quarterly revenue fluctuate?
AMLX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Amylyx Pharmaceuticals, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is AMLX's revenue distributed by segment?
AMLX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does AMLX's revenue compare to industry peers?
Amylyx Pharmaceuticals, Inc. (AMLX) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.